Ezetimibe is a first-in-class cholesterol absorption inhibitor that selectively targets and inhibits the NPC1L1 protein in the small intestine, reducing dietary and biliary cholesterol absorption without affecting bile acid or fat-soluble vitamin uptake . Available as both a monotherapy and in combination with statins (such as rosuvastatin and simvastatin), ezetimibe has become a cornerstone of lipid-lowering therapy . With the global market for ezetimibe preparations exceeding $3 billion and a compound annual growth rate of approximately 4.8%, understanding the buyer landscape is essential for API suppliers and distributors seeking to expand their reach in this critical pharmaceutical segment . Understanding the Ezetimibe Market Landscape Ezetimibe’s clinical utility has grown substantially, driven by its…